Step 1: Is the hypokalemia due to renal K losses or extra-renal K losses?
24 hour urine K was 46 mEq/L so renal K losses were contributing to hypokalemia
Serum magnesium was normal
Patient was not on diuretics👇🏽 2/
In the setting of new onset hypokalemia and new onset HTN, there was high suspicion for mineralocorticoid excess or AME
So, plasma renin activity (PRA) and plasma aldosterone were checked
‼️Both PRA and aldosterone were elevated👇🏽 3/
Common causes of high PRA and high aldosterone in the setting of HTN include:
Renal artery stenosis
Renal artery dissection
Renin producing tumors
Malignant HTN
Renal Artery Doppler did not show evidence of renal artery stenosis 4/
Renin producing tumor was considered to be the likely cause of high PRA/high aldosterone
The source of high renin was likely the underlying leiomyosarcoma as imaging showed progression of disease
5/
Patient was initiated in ACE inhibitors and within 48 hours the serum potassium and BP normalized 👇🏽 6/
Cases of renin producing leiomyosarcoma are rare but have been described 👇🏽
The most anticipated nephrology trial of the year has been published!
“Empagliflozin in Patients with Chronic Kidney Disease” #Kidneywk
@NEJM nejm.org/doi/full/10.10…
EMPA-KIDNEY trial is a randomized, parallel-group, double-blind, placebo-controlled trial designed to assess the effect of empagliflozin on progression of kidney disease & CV disease, & to examine safety profile of the drug in a wide range of pts. w/ CKD
The trial included patients without diabetes, patients with an eGFR of less than 30 ml per minute per 1.73 m2, and patients with low levels of proteinuria
📌 Tweetorial on “IgA Nephropathy: Approach to treatment” based on @goKDIGO webinar by Dr. Richard Lafayette
🔸First step in management of IgAN: Determine the risk of disease progression based on GFR, proteinuria, BP & kidney biopsy findings👇🏽 1/
📌 Approach to treatment of IgAN based on @goKDIGO guidelines👇🏽
🔸This Rx algorithm is NOT applicable to IgA deposition with minimal change disease, IgAN with AKI, IgAN with RPGN, IgA vasculitis, IgA-dominant post-infections GN & secondary forms of IgAN👇🏽 2/
📌 IgAN: All patients should receive supportive care:
🔸 Optimal BP management
🔸 Maximally tolerated ACEi/ARB
🔸 Lifestyle modification
🔸 Reduction of cardiovascular
risk👇🏽
3/
📌 Tweetorial on Diagnosis & Pathogenesis of IgA Nephropathy (IgAN) based on @goKDIGO webinar by @AgnesFogo & Dr. Jurgen Floege #IgAN
🔸Interesting fact: IgAN is not a new disease
First known case of IgAN was found in Prince Joseph of Austria (1776-1847) 1/
📌 IgAN is characterized by:
🔸Mesangial immune-complex deposits which sometimes can extend to the capillary loops & sub-endothelial locations
🔸 Dominant IgA deposits compared to the other immunoglobulins 2/
📌 IgA deposits in IgAN are typically polyclonal & lambda is more prominent than kappa
Dr. Carlos Flombaum from @MSK_Neph gave a holiday lecture full of historic pearls. We are so lucky to have Dr. Flombaum in our division!
Did you know how Cisplatin was ‘accidentally’ discovered?👇🏽 1/
Did you know that allopurinol was first studied as an anti-neoplastic agent. Well, it didn’t work as a cancer therapy but it was eventually used to treat gout and hyperuricemia
2/
In the 1970s, the Renal division at @sloan_kettering was called the Division of Clinical Physiology. Not too surprising as we all know that to be a good nephrologist you have to know physiology
3/